FR2322601A1
(fr)
*
|
1975-09-04 |
1977-04-01 |
Rhone Poulenc Ind |
Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
|
AR208414A1
(es)
*
|
1974-11-07 |
1976-12-27 |
Rhone Poulenc Ind |
Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
|
JPS5680585A
(en)
*
|
1979-11-30 |
1981-07-01 |
Toyoda Gosei Kk |
High pressure hose
|
JPS57144860A
(en)
*
|
1981-03-04 |
1982-09-07 |
Matsushita Electric Ind Co Ltd |
Secondary side water pressure controller for water cooler
|
US4590189A
(en)
*
|
1982-04-02 |
1986-05-20 |
Takeda Chemical Industries, Ltd. |
Condensed pyrrolinone derivatives, their production and use
|
JPS6169773A
(ja)
*
|
1984-09-14 |
1986-04-10 |
Takeda Chem Ind Ltd |
イソインドリノン誘導体
|
JPS6297400U
(xx)
*
|
1985-12-09 |
1987-06-20 |
|
|
FR2607504B1
(fr)
*
|
1986-12-02 |
1989-01-27 |
Rhone Poulenc Sante |
Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2671800B1
(fr)
*
|
1991-01-17 |
1993-03-12 |
Rhone Poulenc Rorer Sa |
Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
|
US5786357A
(en)
|
1991-12-02 |
1998-07-28 |
Sepracor Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
|
AU3275993A
(en)
*
|
1991-12-02 |
1993-06-28 |
Sepracor, Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
|
AU3245593A
(en)
*
|
1991-12-02 |
1993-06-28 |
Sepracor, Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
|
AU4060599A
(en)
|
1998-06-09 |
1999-12-30 |
Takeda Chemical Industries Ltd. |
Pharmaceutical composition for treating or preventing sleep disorders
|
US6339086B1
(en)
|
1999-05-14 |
2002-01-15 |
Swpracor, Inc. |
Methods of making and using N-desmethylzopiclone
|
ES2203319B1
(es)
*
|
2002-04-03 |
2005-03-01 |
Universidad De Oviedo |
Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
|
AU2004305563C1
(en)
|
2003-12-11 |
2011-07-07 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
MX2008000249A
(es)
*
|
2005-07-06 |
2008-03-18 |
Sepracor Inc |
Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
|
JP2009500425A
(ja)
|
2005-07-06 |
2009-01-08 |
セプラコア インコーポレーテッド |
エスゾピクロン及びトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−n−メチル−1−ナフタレンアミン又はトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−1−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
US7476737B2
(en)
*
|
2005-09-05 |
2009-01-13 |
Dr. Reddy's Laboratories Limited |
Eszopiclone process
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
CA2625210A1
(en)
*
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007088073A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Synthon B.V. |
Zopiclone resolution using l-tartaric acid
|
WO2007104035A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007109799A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
EP2007768A2
(en)
*
|
2006-04-20 |
2008-12-31 |
Teva Pharmaceutical Industries Ltd |
Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
|
CN101058581B
(zh)
*
|
2006-04-21 |
2011-06-08 |
天津天士力集团有限公司 |
右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
EP1904499A1
(en)
*
|
2006-06-26 |
2008-04-02 |
Teva Pharmaceutical Industries Ltd |
Process for the preparation of zopiclone
|
MX2009002496A
(es)
*
|
2006-09-08 |
2009-07-10 |
Braincells Inc |
Combinaciones que contienen un derivado de 4-acilaminopiridina.
|
EP2066355A2
(en)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
US7786304B2
(en)
*
|
2006-11-06 |
2010-08-31 |
Centaur Pharmaceutical Pvt. Ltd. |
Process for the preparation of eszopiclone
|
WO2008094690A2
(en)
*
|
2007-01-31 |
2008-08-07 |
Teva Pharmaceutical Industries Ltd. |
Methods for preparing eszopiclone
|
US20080305171A1
(en)
*
|
2007-06-07 |
2008-12-11 |
Kristin Anne Arnold |
Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
|
WO2009002552A1
(en)
*
|
2007-06-25 |
2008-12-31 |
Teva Pharmaceutical Industries Ltd. |
Racemization process of r-zopiclone
|
EP2020403A1
(en)
|
2007-08-02 |
2009-02-04 |
Esteve Quimica, S.A. |
Process for the resolution of zopiclone and intermediate compounds
|
WO2009063486A2
(en)
*
|
2007-08-06 |
2009-05-22 |
Usv Limited |
Process for preparation of dextrorotatory isomer of 6-(5-chloro-pyrid-2-yi)-5-[(4-methyl -1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo [3,4-b] pyrazine (eszopiclone)
|
CA2692955A1
(en)
*
|
2007-12-11 |
2009-07-16 |
Cipla Ltd |
A new method for preparation of zopiclone and its polymorphs
|
US8268832B2
(en)
*
|
2007-12-19 |
2012-09-18 |
Sunovion Pharmaceuticals Inc. |
Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8198278B2
(en)
|
2007-12-19 |
2012-06-12 |
Sunovion Pharmaceuticals Inc. |
Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US20110053945A1
(en)
*
|
2007-12-19 |
2011-03-03 |
Sepracor Inc. |
Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
|
US8269005B2
(en)
*
|
2007-12-19 |
2012-09-18 |
Sunovion Pharmaceuticals Inc. |
L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
CA2812705C
(en)
*
|
2007-12-19 |
2015-08-18 |
Sunovion Pharmaceuticals Inc. |
Maleate, besylate and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
|
CN100467471C
(zh)
*
|
2007-12-19 |
2009-03-11 |
齐鲁天和惠世制药有限公司 |
佐匹克隆的制备方法
|
US8198277B2
(en)
|
2007-12-19 |
2012-06-12 |
Sunovion Pharmaceuticals Inc. |
L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8212036B2
(en)
*
|
2007-12-19 |
2012-07-03 |
Sunovion Pharmaceuticals Inc. |
Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US20100221338A1
(en)
|
2009-01-30 |
2010-09-02 |
Sepracor Inc. |
Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of Coating
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
CN105399745A
(zh)
*
|
2015-12-17 |
2016-03-16 |
天津华津制药有限公司 |
一种吡嗪并羟基吡咯烷酮类化合物的制备方法
|
US11547706B2
(en)
|
2016-06-08 |
2023-01-10 |
President And Fellows Of Harvard College |
Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome
|
CN106220630B
(zh)
*
|
2016-07-23 |
2019-12-10 |
迪嘉药业集团有限公司 |
一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
|
AU2019279858A1
(en)
*
|
2018-05-29 |
2020-11-26 |
President And Fellows Of Harvard College |
Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
|